New insights into diagnosis and therapeutic options for proliferative hepatoblastoma.
Katarzyna B HooksJérôme AudouxHelena FazliSarah LesjeanTony ErnaultNathalie Dugot-SenantThierry Leste-LasserreMartin HagedornBenoit RousseauCoralie DanetSophie BranchereauLaurence BrugièresSophie TaqueCatherine GuettierMonique FabreAnne RullierMarie-Annick BuendiaThérèse CommesChristophe F GrossetAnne Aurélie RaymondPublished in: Hepatology (Baltimore, Md.) (2018)
The highly proliferating C2A subtype is characterized by topoisomerase 2-alpha gene up-regulation and FA pathway activation, and the HB therapeutic arsenal could include bortezomib for the treatment of patients with the most aggressive tumors. (Hepatology 2018;68:89-102).